NCT02076477

The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer（NSCLC）

The Prospective,Multicenter,Randomized Controlled Clinical Study of the Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer（NSCLC）

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 420 (estimated)
• Sponsor: Sichuan Cancer Hospital and Research Institute · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates the optimal intervention time of radiotherapy for oligometastatic stage iv lung cancer.

Conditions

• Oligo-metastatic Stage IV Non-small Cell Lung Cancer

Interventions

Type	Name	Description
RADIATION	concurrent chemoradiotherapy	Radiation（image-guided radiotherapy）：（1）primary tumors≤3cm，Hypofractionated radiation therapy，accumulated dose BED ≥80Gy （central lung cancer），BED ≥100Gy（Peripheral lung cancer）.（2）primary tumors\>3cm，conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（3） regional lymph node:conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（4） Brain metastases： whole brain radiation therapy，36Gy/12f,Intracranial metastases，48Gy/12f.（5） bone metastasis：36 Gy/12f.
DRUG	Docetaxel	Docetaxel:60mg/m2 d1,Given IV
DRUG	pemetrexed	pemetrexed: 500mg/m2 d1,Given IV
DRUG	Cisplatin	Cisplatin：25mg/m2 d1-3，Given IV

Timeline

• Start date: 2014-01-01
• Primary completion: 2020-10-01
• Completion: 2020-10-01
• First posted: 2014-03-03
• Last updated: 2020-03-17

Locations

1 site across 1 country: China